597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase …
WEBThe first six BNT116 doses are administered once weekly during Cycles 1 and 2 and three-weekly from Cycle 3 onwards. The cohort reported here will confirm the dose of BNT116 as monotherapy. Cemiplimab may be added from cycle 3 if tumor samples exhibit PD-L1 expression (tumor proportion score ≥1%).
BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials
WEBAug 25, 2024 · BNT116 is specifically engineered to combat non-small cell lung cancer (NSCLC) and signifies a major progression in the field of personalized medicine. This cutting-edge vaccine...
World's first lung cancer vaccine trial launched in the UK
WEBAug 30, 2024 · The BNT116 vaccine, which has been developed by the German biotechnology company BioNTech (Mainz, Germany) as an immunotherapy treatment for non-small-cell lung cancer (NSCLC), uses mRNA to provide information about common tumour markers to the patient's immune system, so that it is able to identify and mount an immune response to the cancer ...
1st lung cancer vaccine trials launch, powered by COVID mRNA …
WEBAug 25, 2024 · The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first of its kind and has entered phase 1 clinical trials in seven countries.
Lung cancer vaccine trials launched: What you need to know about BNT116
WEBThis innovative vaccine, known as BNT116 and developed by BioNTech, is designed to combat non-small cell lung cancer (NSCLC)—the most common form of the disease.
BioNTech and Regeneron Expand Strategic Collaboration to …
WEBMar 8, 2022 · The investigational mRNA-based cancer vaccine BNT116 is based on BioNTech’s FixVac platform. It consists of a fixed combination of shared tumor-associated antigens that were identified to be frequently expressed in NSCLC.
Lung cancer vaccine: Breakthrough jab could improve survival rates
WEBAug 24, 2024 · Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in …
WEBThe aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer.
A Trial to Learn How the Cancer Vaccine BNT116 in Combination …
WEBThe aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer.
Abstract - American Association for Cancer Research
WEBApr 5, 2024 · BNT116 is an intravenously administered uridine RNA-based lipoplex cancer vaccine comprising six mRNAs (MAGE A3, CLDN6, KK-LC-1, PRAME, MAGE A4, MAGE C1), each encoding a tumor-associated antigen (TAA) frequently expressed in …